Strain Profile
Save

Bifidobacterium breve CECT7263

DEP CECT7263
◔ Human-origin
Sequenced
Public genome assembly available

Bifidobacterium breve CECT7263 is a human milk-derived strain studied in the context of infant feeding and early-life gut health. Multiple randomized controlled trials have evaluated this strain in neonates and infants, including over a one-year period of use in formula-fed babies, and have examined infantile colic as a research topic. Parallel animal model research has examined this species in the context of blood pressure and gut microbiota composition in hypertension-related models. The evidence base for CECT7263 includes strain-specific human trial data, though most is focused on infant populations. These are research topics, not findings; the papers do not establish that this strain treats or prevents any condition.

Where it's been studied

Share of this strain's 8 body-system-tagged papers that concern each system. Research coverage, not measured effect.

Gut 6 papers · 75%
Cardiovascular 3 papers · 38%
Immune 2 papers · 25%
Brain & Mood 1 paper · 13%

Symptoms in the research

Share of this strain's 5 symptom-tagged papers that mention each symptom or condition. Research coverage, not evidence of benefit.

Blood pressure 3 papers · 60%
Diarrhea 1 paper · 20%
IBS 1 paper · 20%

Research

11 papers reference this strain in the probiotic database.

Match confidence
2025 RCT
L.Fermentum CECT5716 and B.Breve CECT7263 on premature infants morbidities: a randomized clinical trial
· Pediatric Research
 2021 ANIMAL
Probiotics Prevent Hypertension in a Murine Model of Systemic Lupus Erythematosus Induced by Toll-Like Receptor 7 Activation
· Nutrients
 2020 ANIMAL
Probiotics Prevent Dysbiosis and the Rise in Blood Pressure in Genetic Hypertension: Role of Short‐Chain Fatty Acids
· Molecular Nutrition & Food Research
 2020 ANIMAL
Probiotic Bifidobacterium breve prevents DOCA‐salt hypertension
· The FASEB Journal
 2020 RCT
Efficacy of Bifidobacterium breve CECT7263 for infantile colic treatment: an open-label, parallel, randomised, controlled trial
· Beneficial Microbes
 2019 RCT
Evaluation of the safety, tolerance and efficacy of 1-year consumption of infant formula supplemented with Lactobacillus fermentum CECT5716 Lc40 or Bifidobacterium breve CECT7263: a randomized controlled trial
· BMC Pediatrics
 2018 WGS
A Gene Homologous to rRNA Methylase Genes Confers Erythromycin and Clindamycin Resistance in Bifidobacterium breve
· Applied and Environmental Microbiology
 2017 WGS
Resequencing the Genome of Bifidobacterium breve Strain CECT7263
· Genome Announcements
 2016 RCT
One year consumption of Bifidobacterium breve CECT7263, a human milk strain is safe in neonates and improves symptoms of infant colic
· Journal of Probiotics & Health
 2025 REVIEW
STRAIN-SPECIFIC EFFICACY OF PROBIOTICS IN MANAGEMENT OF INFANTILE COLIC – A LITERATURE REVIEW
· International Journal of Innovative Technologies in Social Science
 2020 ANIMAL
Microbiota y complicaciones cardiovasculares asociadas al lupus eritematoso sistémico
·
Browse all 11 papers →

Discussion

Be the first to comment.

Sign in to join the discussion.

No comments yet.

Citations

Selected papers that name this strain.

  1. [1]
    Efficacy of Bifidobacterium breve CECT7263 for infantile colic treatment: an open-label, parallel, randomised, controlled trial
    · Beneficial Microbes · 2020
    PMID 33350361 →
  2. [2]
    Evaluation of the safety, tolerance and efficacy of 1-year consumption of infant formula supplemented with Lactobacillus fermentum CECT5716 Lc40 or Bifidobacterium breve CECT7263: a randomized controlled trial
    · BMC Pediatrics · 2019
    PMID 31630683 →